BACKGROUND: Optimal care of persons infected with human immunodeficiency virus type 2 (HIV-2) requires an accurate assessment of HIV-2 plasma viral load (VL), but no clinically approved quantitative HIV-2 RNA VL assay exists. OBJECTIVES: To validate a novel quantitative HIV-2 RNA assay for clinical and research use. STUDY DESIGN: The Abbott m2000sp/rt platform was adapted for quantification of HIV-2 RNA in plasma. Amplification targeted a region of the long terminal repeat conserved in Group A and B HIV-2. Electron microscopy-counted-HIV-2 standards, the WHO/NIBSC HIV-2 International Standard and clinical specimens (N=162) were used to determine the precision, sensitivity, specificity, linear range, accuracy, and clinical performance of the assay. RESULTS: The quantitative linear range of the HIV-2 RNA assay was 10-1,000,000 copies/mL (R(2)>0.99), with a limit of detection of 8 copies/mL (95% CI, 5-18 copies/mL). The assay did not cross-react with HIV-1, and quantification of HIV-2 RNA was not affected by the presence of >5 log(10)HIV-1 RNA copies/mL. The total standard deviation (SD) and intra- and inter-run SD were 0.095, 0.093 and 0.162, respectively, at nominal inputs of 3.7, 1.7 and 1.0 log(10)HIV-2 RNA copies/mL. The HIV-2 WHO/NIBSC International Standard (1000 IU) was shown to contain 152 RNA copies/mL (95% CI 141-163). Overall, HIV-2 RNA was quantified at ≥10 copies/mL from 86 (53%) clinical specimens (median, 2.24 log(10) copies/mL; range 10-16,870), and nine specimens (6%) had HIV-2 RNA detected at <10 copies/mL. CONCLUSIONS: We developed and validated a highly sensitive HIV-2 VL assay that is suitable for clinical and research use.
BACKGROUND: Optimal care of persons infected with human immunodeficiency virus type 2 (HIV-2) requires an accurate assessment of HIV-2 plasma viral load (VL), but no clinically approved quantitative HIV-2 RNA VL assay exists. OBJECTIVES: To validate a novel quantitative HIV-2 RNA assay for clinical and research use. STUDY DESIGN: The Abbott m2000sp/rt platform was adapted for quantification of HIV-2 RNA in plasma. Amplification targeted a region of the long terminal repeat conserved in Group A and B HIV-2. Electron microscopy-counted-HIV-2 standards, the WHO/NIBSC HIV-2 International Standard and clinical specimens (N=162) were used to determine the precision, sensitivity, specificity, linear range, accuracy, and clinical performance of the assay. RESULTS: The quantitative linear range of the HIV-2 RNA assay was 10-1,000,000 copies/mL (R(2)>0.99), with a limit of detection of 8 copies/mL (95% CI, 5-18 copies/mL). The assay did not cross-react with HIV-1, and quantification of HIV-2 RNA was not affected by the presence of >5 log(10)HIV-1 RNA copies/mL. The total standard deviation (SD) and intra- and inter-run SD were 0.095, 0.093 and 0.162, respectively, at nominal inputs of 3.7, 1.7 and 1.0 log(10)HIV-2 RNA copies/mL. The HIV-2 WHO/NIBSC International Standard (1000 IU) was shown to contain 152 RNA copies/mL (95% CI 141-163). Overall, HIV-2 RNA was quantified at ≥10 copies/mL from 86 (53%) clinical specimens (median, 2.24 log(10) copies/mL; range 10-16,870), and nine specimens (6%) had HIV-2 RNA detected at <10 copies/mL. CONCLUSIONS: We developed and validated a highly sensitive HIV-2 VL assay that is suitable for clinical and research use.
Authors: N N Zheng; N B Kiviat; P S Sow; S E Hawes; A Wilson; H Diallo-Agne; C W Critchlow; G S Gottlieb; L Musey; M J McElrath Journal: J Virol Date: 2004-12 Impact factor: 5.103
Authors: J McClure; A M Schmidt; M A Rey-Cuille; J Bannink; L Misher; C C Tsai; D M Anderson; W R Morton; S L Hu Journal: J Med Primatol Date: 2000-08 Impact factor: 0.667
Authors: Geoffrey S Gottlieb; Ndeye Mery Dia Badiane; Stephen E Hawes; Louise Fortes; Macoumba Toure; Cheikh T Ndour; Alison K Starling; Fatou Traore; Fatima Sall; Kim G Wong; Stephen L Cherne; Donovan J Anderson; Stefanie A Dye; Robert A Smith; James I Mullins; Nancy B Kiviat; Papa Salif Sow Journal: Clin Infect Dis Date: 2009-02-15 Impact factor: 9.079
Authors: F Simon; S Matheron; C Tamalet; I Loussert-Ajaka; S Bartczak; J M Pépin; C Dhiver; E Gamba; C Elbim; J A Gastaut Journal: AIDS Date: 1993-11 Impact factor: 4.177
Authors: Philip A Chan; Sarah E Wakeman; Timothy Flanigan; Susan Cu-Uvin; Erna Kojic; Rami Kantor Journal: AIDS Res Ther Date: 2008-08-14 Impact factor: 2.250
Authors: Michael G Berg; Julie Yamaguchi; Elodie Alessandri-Gradt; Robert W Tell; Jean-Christophe Plantier; Catherine A Brennan Journal: J Clin Microbiol Date: 2015-12-23 Impact factor: 5.948
Authors: Eric M Ramos; Socorro Harb; Joan Dragavon; Paul Swenson; Joanne D Stekler; Robert W Coombs Journal: J Clin Virol Date: 2013-08-26 Impact factor: 3.168
Authors: Dana N Raugi; Robert A Smith; Selly Ba; Macoumba Toure; Fatou Traore; Fatima Sall; Charlotte Pan; Lindsey Blankenship; Alexandra Montano; Julia Olson; Ndeye Mery Dia Badiane; James I Mullins; Nancy B Kiviat; Stephen E Hawes; Papa Salif Sow; Geoffrey S Gottlieb Journal: Antimicrob Agents Chemother Date: 2013-04-09 Impact factor: 5.191
Authors: Selly Ba; Dana N Raugi; Robert A Smith; Fatima Sall; Khadim Faye; Stephen E Hawes; Papa Salif Sow; Moussa Seydi; Geoffrey S Gottlieb Journal: Clin Infect Dis Date: 2018-10-30 Impact factor: 9.079
Authors: Ming Chang; Katrin Steinmetzer; Dana N Raugi; Robert A Smith; Selly Ba; Fatima Sall; Moussa Seydi; Alassane Niang; ElHadji Ibrahima Sall; Ousseynou Cisse; Katja Rödel; Robert W Coombs; Geoffrey S Gottlieb Journal: J Clin Virol Date: 2017-10-24 Impact factor: 3.168
Authors: Bharat S Parekh; Chin-Yih Ou; Peter N Fonjungo; Mireille B Kalou; Erin Rottinghaus; Adrian Puren; Heather Alexander; Mackenzie Hurlston Cox; John N Nkengasong Journal: Clin Microbiol Rev Date: 2018-11-28 Impact factor: 26.132
Authors: Dana N Raugi; Robert S Nixon; Sally Leong; Khadim Faye; Jean Phillipe Diatta; Fatima Sall; Robert A Smith; ElHadji Ibrahima Sall; Jean Jacques Malomar; Moussa Seydi; Geoffrey S Gottlieb Journal: J Clin Microbiol Date: 2020-12-17 Impact factor: 5.948